Why Cassava Sciences stock is increasing after hours
Cassava Sciences Inc SAVA shares rise in extended trading on Wednesday following recent insider buying.
The Details: According to a new regulatory filing, director Richard Barry recently purchased a total of 88,841 shares of Cassava Sciences at prices ranging from $25.51 to $26.20 per action.
Barry bought about 11,500 shares on Monday for an average price of $26.13 per share, then bought another 77,276 shares for an average price of $25.76 per share on Tuesday.
In particular, HC Wainwright & Co analyst Vernon Bernardino reiterated cassava with a buy rating and price target of $124 this week.
Did you know that Benzinga tracks insider trading? View recent transactions here.
Cassava Sciences is a clinical-stage biotechnology company focused on Alzheimer's disease.
SAVA Price Action: Cassava has a 52-week high of $51.59 and a 52-week low of $13.84.
The stock is up 9.89% after hours to $27.44 at press time, according to Benzinga Pro.
Photo: Gerd Altmann from Pixabay.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Cassava Sciences Inc SAVA shares rise in extended trading on Wednesday following recent insider buying.
The Details: According to a new regulatory filing, director Richard Barry recently purchased a total of 88,841 shares of Cassava Sciences at prices ranging from $25.51 to $26.20 per action.
Barry bought about 11,500 shares on Monday for an average price of $26.13 per share, then bought another 77,276 shares for an average price of $25.76 per share on Tuesday.
In particular, HC Wainwright & Co analyst Vernon Bernardino reiterated cassava with a buy rating and price target of $124 this week.
Did you know that Benzinga tracks insider trading? View recent transactions here.
Cassava Sciences is a clinical-stage biotechnology company focused on Alzheimer's disease.
SAVA Price Action: Cassava has a 52-week high of $51.59 and a 52-week low of $13.84.
The stock is up 9.89% after hours to $27.44 at press time, according to Benzinga Pro.
Photo: Gerd Altmann from Pixabay.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
What's Your Reaction?